Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy

Table 3

QOL in the DC vaccine and CIK cell therapy group (𝑁=100, censored data in 3 cases).

Improvement in general status, number of patients (%)
	Major (%)	Minor (%)	No change (%)	Worse (%)
Physical strength	50 (51.5)	23 (23.7)	19 (19.6)	5 (5.2)
Appetite	49 (50.5)	23 (23.7)	16 (19.6)	9 (5.2)
Sleeping status	53 (54.6)	17 (17.5)	16 (16.5)	11 (11.4)
Weight	49 (50.5)	19 (19.6)	23 (23.7)	6 (6.2)